Baxter International Inc. was named in a complaint for improperly marketing opioid drugs and revealed an internal probe into the medical supplier’s accounting, sending the company’s shares down.
Researchers at the National Institutes of Health (NIH) and Massachusetts General Hospital (MGH) in Boston published research that found an injectable hormone called tesamorelin decreases liver fat and prevented liver fibrosis in HIV patients affected by non-alcoholic fatty liver disease.
The U.S. FDA approved Janssen’s Xarelto (rivaroxaban) for preventing blood clots in acutely sick patients in hospitals who are at risk for blood clots but who are not at high risk of bleeding.
The U.S. FDA approved a bone-building drug from Pfenex Inc. to treat osteoporosis in certain patients at high risk for fractures, marking the company’s first commercial product.
Prospects for AstraZeneca’s respiratory treatments business improved as a three-drug inhaler was shown to ease smoker’s lung and U.S. regulators granted the company’s injectable asthma drug Fasenra special status for a rare lung condition.
GlaxoSmithKline’s experimental HIV injection is as effective when given every other month as monthly, according to a study
Novo Nordisk’s sales forecast for 2019 was raised due to growing demand for obesity products and a new injectable treatment for diabetes, which is now the company’s growth engine as insulin sales decline.
The new global pharmaceutical company combines Mylan N.V. with Upjohn, Pfizer Inc.’s off-patent branded and generic established medicines business.
A collaboration and license deal was inked with Gilead Sciences Inc. to develop and market a long-acting injectable HIV therapy using Durect Corp.’s SABER technology.
HIV-focused ViiV Healthcare submitted a New Drug Application (NDA) to the Food and Drug Administration for potential approval of the company’s investigational combination treatment for HIV-1.
